Data protection Impressum

Newsroom

HeroSupport, a spin-off from the University Hospitals of Geneva, has obtained CE Mark certification for VENUS SHELL, a personalized 3D-printed breast immobilization system for prone radiotherapy.

HeroSupport receives CE Mark for its VENUS SHELL radiotherapy device

10 March 2026

Lausanne-based Polares Medical has closed an oversubscribed USD 50 million Series C financing round to advance clinical studies of its MRace Posterior Leaflet Replacement system for mitral regurgitation across the US, Europe, and Australia.

Polares Medical raises USD 50 million to advance its mitral valve replacement system

9 March 2026

Alithea Genomics has completed its seed financing round with an additional CHF 3 million, bringing the total to CHF 6.9 million, to accelerate the commercialization of its large-scale RNA sequencing platforms for drug screening and toxicology.

Alithea Genomics raises CHF 6.9 million to industrialize RNA sequencing

9 March 2026

Geneva's University Hospitals (HUG) are launching a dedicated Women's Cardiovascular Health Center to address the underdiagnosis of heart disease in women.

Geneva’s HUG launches a dedicated cardiovascular health center for women

9 March 2026

EPFL spin-off Verretex has secured CHF 1.2 million in dilutive and non-dilutive funding to expand its industrial production of recycled glass fiber textiles and accelerate its entry into new markets.

Verretex raises CHF 1.2 million to scale recycled glass fiber production

4 March 2026

As life sciences companies navigate increasingly complex global markets, the decision of where to establish or expand international operations has become a strategic one.

Why Switzerland

Why Life Sciences Companies Choose Switzerland to Scale Internationally

On 2 March 2026, Switzerland and the European Union signed a broad package of bilateral agreements in Brussels, establishing a modern framework designed to deepen and expand cooperation across trade, health, energy, research, and market access.

Switzerland and the EU sign a comprehensive bilateral agreement package

3 March 2026

Lausanne-based Xsensio has closed an oversubscribed USD 7 million Series A financing round to accelerate clinical deployment of its Lab-on-Skin wearable biosensing platform, with new backing from WI Harper and a collaboration with Texas Instruments.

Xsensio raises USD 7 million to advance its wearable biosensing platform

3 March 2026

Renens-based L.E.S.S. SA has raised CHF 17 million to accelerate the industrial-scale deployment of its proprietary LuxiBright nano-fiber lighting technology across automotive, machine vision, and medical markets.

L.E.S.S. SA raises CHF 17 million to scale its nano-fiber lighting technology

3 March 2026

Bracco Imaging, Limula, and the University of Fribourg have launched an Innosuisse-funded research partnership to automate and reduce the cost of CAR-T cell therapy production.

Bracco, Limula and the University of Fribourg join forces to lower the cost of cell therapies

3 March 2026

1 … 7 8 9 10 11 12 13 14 15 … 93